At the May 4, 2015, meeting, the Board approved a three-year, $14 million clinical trial designed to determine the best dose of aspirin to use to prevent heart attacks and strokes in people with heart disease. The study, called ADAPTABLE (Aspirin Dosing: A Patient-centric TrialAssessing Benefits and Long-term Effectiveness), will compare the benefits and harms of a low- and regular-strength daily dose of aspirin in patients diagnosed with heart disease. (Read more)
The Board also approved $14 million for the first demonstration project to be conducted using PCORnet, the National Patient-Centered Clinical Research Network, as well as plans for two more PCORnet demonstration projects totaling up to $29.5 million in support. (Read more)
All PCORI Board meetings are open to the public and registration to attend in-person meetings is not required. A live webinar was available for those unable to attend in person.
Each in-person public Board meeting includes a public comment period and individuals can register to provide comment on-site. Individuals unable to attend this meeting in person could provide comment via telephone. (Guidelines for Public Comments)
Teleconference Audio Recording